Premium
Particulate‐Based Single‐Dose Local Immunosuppressive Regimen for Inducing Tolerogenic Dendritic Cells in Xenogeneic Islet Transplantation
Author(s) -
Pathak Shiva,
Acharya Suman,
Regmi Shobha,
Shrestha Prakash,
You Zhiwei,
Bae Young Kyung,
Park Min Hui,
Yook Simmyung,
Kim JaeRyong,
Park So Young,
Jeong Daewon,
Yong Chul Soon,
Kim Jong Oh,
Chang Jae Hoon,
Jeong JeeHeon
Publication year - 2021
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202001157
Subject(s) - islet , foxp3 , transplantation , immunology , immune tolerance , medicine , cd8 , dendritic cell , immune system , cancer research , pharmacology , diabetes mellitus , endocrinology
Recent studies emphasize on developing immune tolerance by an interim administration of various immunosuppressive drugs. In this study, a robust protocol is reported for local immunomodulation using a single‐dose of FK506 microspheres and clodronate liposomes (mFK+CLO) in a xenogeneic model of islet transplantation. Surprisingly, the single‐dose treatment with mFK+CLO induce tolerance to the islet xenograft. The recipient mice display tolerogenic dendritic cells (tDCs) with decreased antigen presenting ability and T cell activation capacity. Furthermore, a reduced percentage of CD4 + and CD8 + T cells and an impaired differentiation of naïve CD4 + T cells into interferon‐ γ producing Th1 and interleukin‐17 producing Th17 cells are observed. In addition, the immunosuppressive protocol leads to the generation of Foxp3 + regulatory T cells (Tregs) which are required for the long‐term graft survival. The enhanced generation of tDCs and Tregs by the single treatment of mFK+CLO cause xenograft tolerance, suggesting a possible clinical strategy which may pave the way towards improving therapeutic outcomes of clinical islet transplantation.